MA54940A - Dérivés d'acides aminés pour le traitement de maladies inflammatoires - Google Patents

Dérivés d'acides aminés pour le traitement de maladies inflammatoires

Info

Publication number
MA54940A
MA54940A MA054940A MA54940A MA54940A MA 54940 A MA54940 A MA 54940A MA 054940 A MA054940 A MA 054940A MA 54940 A MA54940 A MA 54940A MA 54940 A MA54940 A MA 54940A
Authority
MA
Morocco
Prior art keywords
treatment
amino acid
acid derivatives
inflammatory diseases
inflammatory
Prior art date
Application number
MA054940A
Other languages
English (en)
Other versions
MA54940B1 (fr
Inventor
Chao Jin
Michael Mullan
Daniel Paris
Original Assignee
The Roskamp Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Roskamp Inst filed Critical The Roskamp Inst
Publication of MA54940A publication Critical patent/MA54940A/fr
Publication of MA54940B1 publication Critical patent/MA54940B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA54940A 2019-01-22 2020-01-22 Dérivés d'acides aminés pour le traitement de maladies inflammatoires MA54940B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962795549P 2019-01-22 2019-01-22
US201962871951P 2019-07-09 2019-07-09
PCT/US2020/014636 WO2020154420A2 (fr) 2019-01-22 2020-01-22 Dérivés d'acides aminés pour le traitement de maladies inflammatoires
EP20708296.7A EP3924349B1 (fr) 2019-01-22 2020-01-22 Dérivés d'acides aminés pour le traitement de maladies inflammatoires

Publications (2)

Publication Number Publication Date
MA54940A true MA54940A (fr) 2021-12-22
MA54940B1 MA54940B1 (fr) 2025-09-30

Family

ID=69726748

Family Applications (1)

Application Number Title Priority Date Filing Date
MA54940A MA54940B1 (fr) 2019-01-22 2020-01-22 Dérivés d'acides aminés pour le traitement de maladies inflammatoires

Country Status (30)

Country Link
US (1) US20220081415A1 (fr)
EP (1) EP3924349B1 (fr)
JP (2) JP7784708B2 (fr)
KR (1) KR20210141930A (fr)
CN (1) CN113614074A (fr)
AU (2) AU2020211980B2 (fr)
BR (1) BR112021014372A2 (fr)
CA (1) CA3127246A1 (fr)
CL (1) CL2021001944A1 (fr)
CO (1) CO2021010931A2 (fr)
DK (1) DK3924349T3 (fr)
EC (1) ECSP21062210A (fr)
ES (1) ES3038582T3 (fr)
FI (1) FI3924349T3 (fr)
HR (1) HRP20251058T1 (fr)
HU (1) HUE072722T2 (fr)
IL (1) IL284980B1 (fr)
LT (1) LT3924349T (fr)
MA (1) MA54940B1 (fr)
MD (1) MD3924349T2 (fr)
MX (1) MX2021008748A (fr)
PH (1) PH12021551760A1 (fr)
PL (1) PL3924349T3 (fr)
PT (1) PT3924349T (fr)
RS (1) RS67095B1 (fr)
SG (1) SG11202107977TA (fr)
SI (1) SI3924349T1 (fr)
SM (1) SMT202500289T1 (fr)
WO (1) WO2020154420A2 (fr)
ZA (1) ZA202105229B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019389168A1 (en) 2018-11-30 2021-06-24 Comet Therapeutics, Inc. Pantetheine derivatives and uses thereof
AU2024411297A1 (en) 2023-12-24 2026-07-23 Alkapharmics Potent nf-kb inhibitors for the treatment of inflammatory diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1999011658A1 (fr) * 1997-08-29 1999-03-11 Proteus Molecular Design Ltd. Derives de meta-benzamidine comme inhibiteurs de serine protease
US6218390B1 (en) * 1998-12-17 2001-04-17 Synaptic Pharmaceutical Corporation Morpholinone and morpholine derivatives and uses thereof
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8710069B2 (en) * 2008-03-27 2014-04-29 University Of Kentucky Research Foundation Opioid-nornicotine codrugs combinations for pain management
EP2331499B1 (fr) * 2008-08-19 2016-09-21 Janssen Pharmaceutica NV Antagonistes des récepteurs au froid activés par le menthol
WO2010127058A1 (fr) * 2009-05-01 2010-11-04 Profectus Biosciences, Inc. Dérivés de benzamide et de naphtamide inhibant le facteur nucléaire kappa(b) (nf-kb)

Also Published As

Publication number Publication date
EP3924349B1 (fr) 2025-06-25
AU2025283544A1 (en) 2026-01-15
WO2020154420A3 (fr) 2020-09-10
AU2020211980B2 (en) 2025-09-18
WO2020154420A4 (fr) 2020-11-12
FI3924349T3 (fi) 2025-08-29
BR112021014372A2 (pt) 2021-09-28
CN113614074A (zh) 2021-11-05
ECSP21062210A (es) 2022-06-30
JP2022524571A (ja) 2022-05-09
KR20210141930A (ko) 2021-11-23
HUE072722T2 (hu) 2025-12-28
DK3924349T3 (da) 2025-09-08
MX2021008748A (es) 2022-01-24
SI3924349T1 (sl) 2025-10-30
ES3038582T3 (en) 2025-10-14
LT3924349T (lt) 2025-10-10
CL2021001944A1 (es) 2022-05-06
CA3127246A1 (fr) 2020-07-30
AU2020211980A1 (en) 2021-08-19
JP7784708B2 (ja) 2025-12-12
PH12021551760A1 (en) 2022-05-30
SMT202500289T1 (it) 2025-11-10
PT3924349T (pt) 2025-10-01
ZA202105229B (en) 2022-12-21
IL284980A (en) 2021-09-30
MA54940B1 (fr) 2025-09-30
RS67095B1 (sr) 2025-09-30
EP3924349A2 (fr) 2021-12-22
CO2021010931A2 (es) 2022-01-17
US20220081415A1 (en) 2022-03-17
PL3924349T3 (pl) 2025-09-22
HRP20251058T1 (hr) 2025-11-07
MD3924349T2 (ro) 2025-11-30
JP2025062004A (ja) 2025-04-11
WO2020154420A2 (fr) 2020-07-30
SG11202107977TA (en) 2021-08-30
IL284980B1 (en) 2026-05-01

Similar Documents

Publication Publication Date Title
EP3952902A4 (fr) Formes posologiques et schémas de traitement pour des composés d'acides aminés
MA54515A (fr) Dérivés de quinoléine destinés à être utilisés dans le traitement de maladies inflammatoires
MA56019A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA55560A (fr) Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer
EP3866781A4 (fr) Nouvelles compositions pour le traitement de maladies inflammatoires
MA55604A (fr) Dérivés de pyrrolotriazine pour le traitement de maladies médiées par kit et pdgfra
MA50763A (fr) Compositions d'acides aminés et méthodés de traitement de maladies et troubles musculaires
MA55325A (fr) Composés pour le traitement de maladies pd-l1
EP3820537A4 (fr) Vecteurs de thérapie génique pour le traitement de la maladie de danon
MX2018005694A (es) 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas.
EP4045037C0 (fr) Hétéroaryl-biphénylamines pour le traitement de maladies pd-l1
MA51524A (fr) Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3829569A4 (fr) Formulations de spinosyne pour le traitement de maladies oculaires et faciaux provoquées par demodex
MA49906A (fr) Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie
EP3790867A4 (fr) Inhibiteurs de kdm1a pour le traitement d'une maladie
EP3866777A4 (fr) Polythérapie pour le traitement de maladies inflammatoires
EP3934646A4 (fr) Compositions pharmaceutiques pour le traitement de maladies ou de troubles oculaires
MA53614A (fr) Protéine pour le traitement de maladies inflammatoires
MA54077A (fr) Polythérapie pour le traitement de maladies hématologiques
EP3649256A4 (fr) Procédés de traitement d'une inflammation et de maladies et troubles associés par inhibition de la protéine kinase alpha 1
EP3593803A4 (fr) Composés destinés au traitement de maladies causées par l'accumulation d'oxalate
EP3877383A4 (fr) Composés et compositions pour le traitement de maladies respiratoires
EP4073060A4 (fr) Inhibiteurs de l'histone déméthylase spécifique de la lysine pour le traitement de néoplasmes myéloprolifératifs
EP3766503A4 (fr) Application d'un inhibiteur de micro-arn-210 dans la préparation de médicaments destinés au traitement de maladies cutanées inflammatoires